InSightec announced that it is partnering with the American College of Radiology Imaging Network (ACRIN) to enroll patients in a phase II study assessing how effectively its ExAblate 2000 technology can ablate breast tumors.
The Haifa, Israel-based firm said that the ExAblate 2000 combines MRI with highly focused ultrasound to noninvasively thermally ablate tumors in the body. Currently, the technology is used to treat uterine fibroids.
The phase II trial is intended to demonstrate that ExAblate 2000 can effectively and noninvasively ablate localized tumors compared to conventional lumpectomy, according to the firm. The study will involve 200 patients at up to 10 sites worldwide, InSightec said.By AuntMinnie.com staff writers
November 22, 2005
Copyright © 2005 AuntMinnie.com